GUFICBIONSEGufic Biosciences Limited· PharmaceuticalsLowNeutral
Announced Tue, 15 Jul · 17:56 IST

Gufic Biosciences Limited has informed the Exchange about Intimation of Allotment of Equity Shares of Gufic Prime Private Limited ( Subsidiary Company ) through Rights Issue

Business Updates View source PDF

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Gufic Biosciences has been allotted 512,000 equity shares (face value Re. 1 each) of its subsidiary Gufic Prime Private Limited (GPPL) through a Rights Issue on July 14, 2025. The total investment amounts to Rs. 5.12 lakh in cash. After this allotment, Gufic Biosciences holds 600,000 equity shares, representing 60% of the total shareholding in GPPL. GPPL is engaged in marketing, distribution and sale of pharmaceutical products in India, and its business is in line with Gufic's main line of business. GPPL was incorporated on November 18, 2023, and is yet to commence business operations with nil turnover. The transaction is at arm's length and falls within related party transactions as GPPL is a subsidiary.

Likely market impact

This is a routine capital infusion into a subsidiary that is not yet operational. The amount is small (Rs. 5.12 lakh) and is unlikely to have any material impact on Gufic Biosciences' financials or stock price. It strengthens the company's hold (60%) in its pharma distribution subsidiary.